Chronic Myeloid Leukemia Treatment
Introduction to Tyrosine Kinase Inhibitors
- The American College of Hematology recommends that dasatinib and nilotinib show better results in patients with Chronic Myeloid Leukemia (CML) in the chronic phase, with complete cytogenetic response (CCyR) rates of 50% and 45%, respectively, in second-line treatment 1
Second-Line Treatment After Imatinib
- In second-line treatment after imatinib, the CCyR rate is 50% in patients resistant or intolerant to imatinib, with a median time to achieve CCyR of 2.9 months in resistant patients and 2.8 months in intolerant patients, and 86% of patients maintain CCyR at 24 months 1, 2
- The CCyR rate in second-line treatment after imatinib is 45% in patients resistant or intolerant to imatinib, with a median time to response of 2.8 months 1, 2
Treatment Outcomes Based on Resistance and Intolerance
- In patients intolerant to imatinib and dasatinib, the CCyR rate is 40%, while in patients resistant to imatinib and nilotinib, it is 31%, and in those resistant to imatinib and dasatinib, it is 22% 1
- In patients with resistance or intolerance to dasatinib or nilotinib, the CCyR rate is 49% 1
- In patients with the T315I mutation, the CCyR rate is 70% 1
Factors Influencing Treatment Response
- Previous resistance to other tyrosine kinase inhibitors (TKIs) decreases the likelihood of achieving CCyR with subsequent therapies, according to the National Comprehensive Cancer Network 1
- The presence of mutations, especially T315I, significantly affects the response, with ponatinib being the only commercially effective TKI against this mutation, as per the European Society for Medical Oncology 3
Time to Response and Treatment Monitoring
- Early molecular response (≤10% BCR-ABL1 IS at 3 months) is an important predictor of survival, and patients not achieving cytogenetic or molecular response at 3, 6, or 12 months should be considered for alternative therapies, as recommended by the National Comprehensive Cancer Network 1
- Regular monitoring is crucial to evaluate treatment response, with assessments at 3, 6, and 12 months for complete hematological response, cytogenetic response, and molecular response, respectively 1